Skip to main content
Equibles
MIRM logo

MIRM · Mirum Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio

Track MIRM — free

Use MIRM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MIRM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$87.97 +0.43 (+0.49%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$5.82B
Shares
64.93M
Volume · Sep 30 901.77K Avg daily vol (3M) 686.18K

Mirum Pharmaceuticals, Inc. Earnings Call Transcripts

Quarterly earnings calls for Mirum Pharmaceuticals, Inc. (MIRM), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲275.6% $18.78M −$35.71M '22 Q3 22-11-09 ▲789.3% $27.91M −$36.43M '22 Q4 23-01-09 ▲145.1% $31.60M −$30.13M '23 Q1 23-05-04 ▲114.5% $37.50M −$74.04M '23 Q2 23-08-03 ▲154.1% $47.73M −$23.59M '23 Q3 23-11-02 ▲149.2% $69.55M −$35.66M '23 Q4 24-02-28 ▲119.1% $69.22M −$25.28M '24 Q1 24-05-08 ▲107.7% $77.88M −$24.64M '24 Q2 24-08-07 ▲89.4% $90.38M −$14.23M '24 Q3 24-11-12 ▲42.9% $99.41M −$23.79M '24 Q4 25-01-13 ▲61.2% $111.58M −$14.68M '25 Q1 25-05-07 ▲64.1% $127.78M −$5.86M '25 Q2 25-08-06 ▲47.2% $133.01M $2.90M '25 Q3 25-11-04 ▲49.8% $148.93M −$5.73M '25 Q4 26-02-25 ▲43.3% $159.88M −$790.15M '26 Q1 26-05-06 LATEST ▲37.9% $176.24M −$67.23M '26 Q2 26-08-05
Conference
Investor event
2026-09-16
Mirum Pharmaceuticals, Inc. (MIRM) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-15
Mirum Pharmaceuticals, Inc. (MIRM) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
Positive tone Velixabat PSC/VISTA regulatory delay Velixabat PBC/Vantage study Commercial sales and guidance raise
Revenue
$176.24M
▲ 37.9% YoY
Diluted EPS
$-1.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-19
Mirum Pharmaceuticals, Inc. (MIRM) May 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript
Confident tone ZalurgoCertid / FOP licensing Rare liver disease pipeline (PSC, hepatitis delta) Livmarly / PFIC commercial performance
Revenue
$159.88M
▲ 43.3% YoY
Diluted EPS
$-13.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript
Confident tone Pipeline and registrational readouts Volixibat VISTA study in PSC Pediatric cholestatic expansion (EXPAND)
Revenue
$148.93M*
▲ 49.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 Earnings Call Transcript
Confident tone LIVMARLI franchise (Alagille and PFIC) Volixibat VISTAS Phase IIb in PSC Pipeline expansion (EXPAND, MRM-3379 in Fragile X)
Revenue
$133.01M
▲ 47.2% YoY
Diluted EPS
$0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript
Confident tone Livmarli U.S. performance (PFIC, Alagille, new formulation) Volixibat VISTAS Phase IIb in PSC International Livmarli expansion (Europe, Japan via Takeda)
Revenue
$127.78M
▲ 64.1% YoY
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript
Confident tone LIVMARLI performance and tablet launch Pipeline: Volixibat VISTAS in PSC Pipeline: Volixabat VANTAGE in PBC and EASL data
Revenue
$111.58M
▲ 61.2% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript
Confident tone OCA competition in PBC Livmarly EXPAND study (broader cholestatic pruritus) 2025 financial guidance
Revenue
$99.41M*
▲ 42.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript
Confident tone LIVMARLI commercial growth Volixibat pipeline (PBC/PSC) CHENODAL/CTX PDUFA
Revenue
$90.38M
▲ 89.4% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call
Revenue
$77.88M
▲ 107.7% YoY
Diluted EPS
$-0.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript
Confident tone PFIC label expansion Volixibat interim analysis LIVMARLI commercial growth
Revenue
$69.22M
▲ 119.1% YoY
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript
Confident tone LIVMARLI commercial growth Volixibat pipeline (VISTAS/VANTAGE) 2024 financial guidance
Revenue
$69.55M*
▲ 149.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript
Revenue
$47.73M
▲ 154.1% YoY
Diluted EPS
$-0.57
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2023 Earnings Call Transcript
Revenue
$37.50M
▲ 114.5% YoY
Diluted EPS
$-1.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2023 Earnings Call Transcript
Revenue
$31.60M
▲ 145.1% YoY
Diluted EPS
$-0.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Call Transcript
Revenue
$27.91M*
▲ 789.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2022 Earnings Call Transcript
Revenue
$18.78M
▲ 275.6% YoY
Diluted EPS
$-1.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2022 Earnings Call Transcript
Revenue
$17.48M
▲ 58.9% YoY
Diluted EPS
$-0.84
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2022 Earnings Call Transcript
Revenue
$12.89M
Diluted EPS
$-1.17
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-09
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2021 Earnings Call Transcript
Revenue
$3.14M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2021 Earnings Call Transcript
Revenue
$5.00M
Diluted EPS
$-1.55
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2021 Earnings Call Transcript
Revenue
$11.00M
Diluted EPS
$-1.45
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2021 Earnings Call Transcript
Revenue
$
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 earnings calls
Key facts CIK 1759425 CUSIP 604749101 13F (30d) 9 filings 8 filers Visit website Investor relations